Promise Bio has officially exited stealth mode, securing $8.3 million in seed funding led by Awz Ventures, along with contributions from Pfizer and AstraZeneca. The Tel Aviv-based biotech firm aims to revolutionize precision medicine for autoimmune diseases through its innovative cloud-based AI platform that detects Post-Translational Modifications (PTMs) in proteins from a single blood sample. This technology significantly streamlines testing, paving the way for more effective treatments. CEO Ronel Veksler emphasizes the need for a shift from outdated trial-and-error methods in managing autoimmune disorders, which affect around 4% of the global population.